With its unique cTAŽ and data-driven decision support platform, Flagship offers its pharmaceutical partners robust, actionable data for informed decision making during clinical development
SANTA CLARA, California, Sept. 18, 2018 /PRNewswire/ -- Based on its recent analysis of the global market for artificial intelligence (AI)-based pathology solutions in immuno-oncology (I-O), Frost & Sullivan recognizes
Photo - https://mma.prnewswire.com/media/736350/Flagship_Biosciences_Award.jpg
"Flagship was one of the early adopters of digital pathology, leveraging AI-based image analysis methods to generate reproducible, quantifiable, precise data to aid decision-making through the entire drug development process," said Unmesh Lal, Program Manager at Frost & Sullivan. "Its cTAŽ platform generates vast amounts of cell-specific biological measurements, such as spatial tissue organization, as well as cellular interactions and architectures, to deliver data-rich tissue content identifying immune cell infiltration within the tumor microenvironment. Flagship's team then interprets these profiles, characterizes patient-specific immunomodulation, and predicts patient response to cancer immunotherapies."
The company works alongside pharmaceutical companies all over the world to create biomarker strategies for I-O therapeutic-CDx co-development in underserved areas, including I-O, fibrosis, and rare neuromuscular diseases like Duchenne muscular dystrophy. Flagship employs best practices across all sub-processes, from tissue collection and processing to digital whole-slide imaging and quantitative tissue biomarker interpretations to provide end-to-end services to help its pharmaceutical partners successfully develop and commercialize drugs.
Significantly, Flagship can analyze individual slides within minutes and develop useful pathology scores in days; conversely, manual pathology methods take months. It eliminates the need for pathologist scoring development and concordance studies, as the software needs to generate data from the slide only once; it can explore multiple scoring interpretations without developing a new image analysis algorithm.
"While Flagship's cutting-edge, comprehensive quantitative pathology solutions have entrenched it in the drug development market, it is also looking to expand its application scope to cover pathology," noted Lal. "As its database and experience expand, the company will seek real-world applications for its cTAŽ platform under a productized model to offer widespread use in clinical laboratories. Flagship is also likely to reveal some of its commercial partnerships within a year, thereby cementing its leadership position and extending its brand beyond drug development."
Each year, Frost & Sullivan presents this award to the company that develops a product with innovative features and functionality that is gaining rapid acceptance in the market. The award recognizes the quality of the solution and the customer value enhancements it enables.
Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.
About Flagship Biosciences
Flagship Biosciences, Inc. develops and provides tissue image analysis and quantitative tissue biomarker solutions. The company offers Computational Tissue Analysis (cTA) platform for quantitative, contextual tissue interpretation, evaluation, and interrogation. It caters to pharmaceutical, biotechnology, and medical device companies. Flagship Biosciences, Inc. was founded in 2009 and is headquartered in Broomfield, Colorado
Amy ShannonP: 303-908-6008E: email@example.com
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the discussion.
Samantha ParkP: 210.247.2426F: 210.348.1003E: firstname.lastname@example.org
Subscribe to our Free Newsletters!